Lexaria Bioscience Reaches Full Enrollment for GLP-1 Human Pilot Study #7
Lexaria Bioscience Corp. has achieved full enrollment and continues dosing for its Human Pilot Study #7, which evaluates oral DehydraTECH-semaglutide compositions.
Stocks · News reference
Lexaria Bioscience Says Australian Tax Refund And Institutional Financing Priced At $12.92/Share Yielded $7.9M Net, About $4.60/Share In Cash On 2.1 Million Shares Outstanding; Says No Further Financings Planned In 2026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lexaria Bioscience Announces Results From Animal Study GLP-1-A26-1 Evaluating Both DehydraTECH-CBD Compositions And DehydraTECH-Semaglutide; Unfortunately, The DHT-SEMA Concentrations In Brain Tissue Were All At Levels Below The Lower Limit Of Quantitation Of The Bioassay Utilized In This Study
Lexaria Bioscience shares are trading higher after the company announced an update on its financial position, showing cash on hand reaching ~$4.60 per share following $7.9 million in recent net proceeds.